Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2108637 | 1.00 | TYMP (0.46) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL15841328 | 0.99 | TYMP (0.45) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL19971896 | 0.99 | TYMP (0.45) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL15841327 | 0.99 | TYMP (0.45) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL3918341 | 0.96 | TYMP (0.48) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL13715991 | 0.96 | TYMP (0.48) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL3918343 | 0.96 | TYMP (0.48) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL15261068 | 0.90 | TYMP (0.48) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL15260893 | 0.90 | TYMP (0.48) | TYMPP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL2116483 | 0.89 | TYMP (0.47) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509485-B2 | Method for producing nucleic acid oligomer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20250145655-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-05-08 | — | — | US | disclosed |
| EP-4488282-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | Sumitomo Chemical Company, Limited (JP) | 2025-01-08 | — | — | EP | disclosed |
| US-20240051986-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-02-15 | — | — | US | disclosed |
| EP-4219520-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-1995253-B1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | NIPPON SHINYAKU CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-8859755-B2 | Method for preparing ribonucleoside phosphorothioate | CHIRALGEN, LTD. (JP) | 2014-10-14 | — | — | US | disclosed |
| US-20130184450-A1 | METHOD FOR PREPARING RIBONUCLEOSIDE PHOSPHOROTHIOATE | THE UNIVERSITY OF TOKYO (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-1795536-B1 | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | NIPPON SHINYAKU CO LTD (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8158775-B2 | Method for detaching protecting group on nucleic acid | NIPPON SHINYAKU CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090312534-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | NIPPON SHINYAKU CO., LTD. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090149645-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | NIPPON SHINYAKU CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | NIPPON SHINYAKU CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2017282-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-1995252-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | Nippon Shinyaku Co., Ltd. (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995253-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20070282097-A1 | Phosphoramidite Compound And Method For Producing Oligo-Rna | NIPPON SHINYAKU CO., LTD. (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1795536-A1 | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | Nippon Shinyaku Co., Ltd. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145655-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | POLRMT, RNGTT, POLM | TYMP 458/4885P2RY2 2861/4885P2RY4 2389/4885 |
| US-20240051986-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | POLRMT, NOP2, POLN | TYMP 689/4885P2RY2 3439/4885P2RY4 2080/4885 |
| US-20090312534-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | NSUN2, RNASEH1, RNASE1 | TYMP 321/4885P2RY2 4819/4885P2RY4 4822/4885 |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | RNGTT, DUT, ADAR | TYMP 122/4885P2RY2 1513/4885P2RY4 1416/4885 |
| US-12509485-B2 | Method for producing nucleic acid oligomer | RNGTT, POLM, NSUN2 | TYMP 365/4885P2RY2 2712/4885P2RY4 1915/4885 |
| US-20070282097-A1 | Phosphoramidite Compound And Method For Producing Oligo-Rna | NSUN2, NSUN3, XRN2 | TYMP 485/4885P2RY2 1095/4885P2RY4 2054/4885 |
| US-20130184450-A1 | METHOD FOR PREPARING RIBONUCLEOSIDE PHOSPHOROTHIOATE | RNGTT, RNMT, TRDMT1 | TYMP 116/4885P2RY2 3157/4885P2RY4 2112/4885 |
| US-20090149645-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | DNASE1, DNASE1L3, NSUN2 | TYMP 149/4885P2RY2 4225/4885P2RY4 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.